Los Angeles Capital Management LLC Buys 55,305 Shares of Phibro Animal Health Corporation $PAHC

Los Angeles Capital Management LLC boosted its holdings in Phibro Animal Health Corporation (NASDAQ:PAHC) by 250.3% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 77,397 shares of the company’s stock after buying an additional 55,305 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.19% of Phibro Animal Health worth $1,977,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Nuveen LLC acquired a new stake in Phibro Animal Health during the 1st quarter valued at approximately $10,312,000. Invesco Ltd. increased its stake in Phibro Animal Health by 92.3% during the 1st quarter. Invesco Ltd. now owns 387,739 shares of the company’s stock valued at $8,282,000 after purchasing an additional 186,087 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Phibro Animal Health by 74.3% in the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after acquiring an additional 154,281 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Phibro Animal Health by 711.1% in the first quarter. Russell Investments Group Ltd. now owns 122,600 shares of the company’s stock valued at $2,619,000 after purchasing an additional 107,485 shares in the last quarter. Finally, Brant Point Investment Management LLC purchased a new position in Phibro Animal Health during the 1st quarter worth $2,216,000. 99.34% of the stock is currently owned by institutional investors.

Phibro Animal Health Trading Down 1.1%

Shares of Phibro Animal Health stock opened at $45.33 on Wednesday. The firm has a market cap of $1.84 billion, a price-to-earnings ratio of 38.42, a PEG ratio of 1.24 and a beta of 0.81. Phibro Animal Health Corporation has a twelve month low of $16.16 and a twelve month high of $46.42. The business has a 50-day moving average price of $40.06 and a 200-day moving average price of $31.43. The company has a quick ratio of 1.25, a current ratio of 2.76 and a debt-to-equity ratio of 2.46.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.15. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%.The business had revenue of $363.89 million for the quarter, compared to the consensus estimate of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. Equities research analysts anticipate that Phibro Animal Health Corporation will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 17th. Stockholders of record on Wednesday, November 26th will be given a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, November 26th. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.1%. Phibro Animal Health’s payout ratio is presently 28.92%.

Insider Transactions at Phibro Animal Health

In other Phibro Animal Health news, CEO Jack Bendheim sold 38,303 shares of the firm’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $45.29, for a total value of $1,734,742.87. Following the completion of the sale, the chief executive officer owned 20,577 shares of the company’s stock, valued at approximately $931,932.33. This trade represents a 65.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders sold 109,159 shares of company stock worth $4,620,198. Corporate insiders own 50.13% of the company’s stock.

Wall Street Analysts Forecast Growth

PAHC has been the topic of several research reports. Bank of America boosted their price target on shares of Phibro Animal Health from $19.00 to $27.00 and gave the company an “underperform” rating in a research report on Friday, August 29th. Morgan Stanley set a $34.00 price objective on Phibro Animal Health in a research note on Thursday, August 28th. JPMorgan Chase & Co. raised their price target on shares of Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Weiss Ratings raised shares of Phibro Animal Health from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, November 5th. Finally, Zacks Research raised Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 29th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Phibro Animal Health currently has a consensus rating of “Hold” and a consensus price target of $31.40.

Phibro Animal Health Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.